Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1067/mph.2002.129363 | DOI Listing |
J Prev Alzheimers Dis
January 2025
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address:
Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).
Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.
Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.
Afr J Reprod Health
December 2024
Department of Epidemiology and Population Health, School of Public Health & Information Sciences, University of Louisville, Louisville, Kentucky, USA.
It is sometimes said that when America sneezes, the world catches a cold. The opposite scenario may also apply: a healthy and progressive American economy and democracy provides needed resources and hope to many parts of the world, including Africa. Four years ago, we wrote an optimistic message in this journal.
View Article and Find Full Text PDFFront Public Health
January 2025
Department of Psychiatry, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!